Agendia nabbed a $6.8 million grant from the European Commission to use its diagnostic technology to identify certain subtypes of colorectal cancer, a boost for the company as it forges ahead with its products and gains regulatory approval for its tests.
Agendia has pulled in $65 million in a private round of equity financing, with plans to use the massive cash infusion to advance and expand commercial development of its cancer-focused molecular diagnostic tests.
Dutch molecular cancer diagnostic company Agendia has closed $23 million in series E financing. The round was led by an undisclosed family investment firm that provided approximately half of the
Hyperion lands $40M in second round VENTURE CAPITALCOMPANY AMOUNT/ROUNDLEAD INVESTORSDESCRIPTION Hyperion Therapeutics South San
Amsterdam-based Agendia, a molecular diagnostics company, has raised $34 million in its fourth venture round, adding ING to its list of backers. Current investors Van Herk Biotech, Gilde Healthcare